Temat: "migraine" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles.
Autorzy :: Hautakangas H; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Winsvold BS; Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.; K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Neurology, Oslo University Hospital, Oslo, Norway.
Ruotsalainen SE; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Bjornsdottir G; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
Harder AVE; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Kogelman LJA; Danish Headache Center, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark.
Thomas LF; K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; BioCore - Bioinformatics Core Facility, Norwegian University of Science and Technology, Trondheim, Norway.; Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Noordam R; Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, the Netherlands.
Benner C; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Gormley P; GlaxoSmithKline, Cambridge, MA, USA.
Artto V; Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland.
Banasik K; Novo Nordic Foundation Center for Protein Research, Copenhagen University, Copenhagen, Denmark.
Bjornsdottir A; Neurology Private Practice, Laeknasetrid, Reykjavik, Iceland.
Boomsma DI; Netherlands Twin Register, Department of Biological Psychology, Vrije Universiteit, Amsterdam, the Netherlands.
Brumpton BM; K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Burgdorf KS; Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Buring JE; Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Chalmer MA; Danish Headache Center, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark.
de Boer I; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Dichgans M; Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany.; Munich Cluster for Systems Neurology (Synergy), Munich, Germany.
Erikstrup C; Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
Färkkilä M; Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland.
Garbrielsen ME; K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Ghanbari M; Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Hagen K; Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.; Clinical Research Unit Central Norway, St. Olavs University Hospital, Trondheim, Norway.
Häppölä P; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Hottenga JJ; Netherlands Twin Register, Department of Biological Psychology, Vrije Universiteit, Amsterdam, the Netherlands.
Hrafnsdottir MG; Landspitali University Hospital, Reykjavik, Iceland.
Hveem K; K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; HUNT Research Center, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Johnsen MB; K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Research and Communication Unit for Musculoskeletal Health (FORMI), Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.
Kähönen M; Department of Clinical Physiology, Tampere University Hospital, and Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Kristoffersen ES; Research and Communication Unit for Musculoskeletal Health (FORMI), Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.; Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway.; Department of Neurology, Akershus University Hospital, Lørenskog, Norway.
Kurth T; Institute of Public Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Lehtimäki T; Department of Clinical Chemistry, Fimlab Laboratories, and Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Lighart L; Netherlands Twin Register, Department of Biological Psychology, Vrije Universiteit, Amsterdam, the Netherlands.
Magnusson SH; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
Malik R; Institute for Stroke and Dementia Research, University Hospital, LMU Munich, Munich, Germany.
Pedersen OB; Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark.
Pelzer N; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Penninx BWJH; Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.; GGZ inGeest Specialized Mental Health Care, Amsterdam, the Netherlands.
Ran C; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Ridker PM; Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Rosendaal FR; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
Sigurdardottir GR; Neurology Private Practice, Laeknasetrid, Reykjavik, Iceland.
Skogholt AH; K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Sveinsson OA; Landspitali University Hospital, Reykjavik, Iceland.
Thorgeirsson TE; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
Ullum H; Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Vijfhuizen LS; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Widén E; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
van Dijk KW; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.; Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.
Aromaa A; National Public Health Institute (Finnish Institute for Health and Welfare - THL), Helsinki, Finland.
Belin AC; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Freilinger T; Klinikum Passau, Department of Neurology, Passau, Germany.; Centre of Neurology, Hertie Institute for Clinical Brain Research, Tuebingen, Germany.
Ikram MA; Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Järvelin MR; Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK.; Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland.; Unit of Primary Health Care, Oulu University Hospital, Oulu, Finland.; Department of Life Sciences, College of Health and Life Sciences, Brunel University London, London, UK.
Raitakari OT; Centre for Population Health Research, University of Turku and Turku University Hospital, Turku, Finland.; Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland.; Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland.
Terwindt GM; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
Kallela M; Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland.
Wessman M; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.; Folkhälsan Research Center, Helsinki, Finland.
Olesen J; Danish Headache Center, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark.
Chasman DI; Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Nyholt DR; School of Biomedical Sciences and Centre for Genomics and Personalised Health, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia.
Stefánsson H; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
Stefansson K; deCODE genetics/Amgen Inc., Reykjavik, Iceland.
van den Maagdenberg AMJM; Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
Hansen TF; Danish Headache Center, Department of Neurology, Copenhagen University Hospital, Copenhagen, Denmark.; Novo Nordic Foundation Center for Protein Research, Copenhagen University, Copenhagen, Denmark.
Ripatti S; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Public Health, University of Helsinki, Helsinki, Finland.
Zwart JA; Department of Research, Innovation and Education, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.; K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Palotie A; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.; Analytic and Translational Genetics Unit, Department of Medicine, Department of Neurology and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.; The Stanley Center for Psychiatric Research and Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Pirinen M; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland. .; Department of Public Health, University of Helsinki, Helsinki, Finland. .; Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland. .; Pokaż więcej
Corporate Authors :: International Headache Genetics Consortium
HUNT All-in Headache
Danish Blood Donor Study Genomic Cohort
Źródło :: Nature genetics [Nat Genet] 2022 Feb; Vol. 54 (2), pp. 152-160. Date of Electronic Publication: 2022 Feb 03.
Typ publikacji :: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :: Genetic Predisposition to Disease*
Genome-Wide Association Study*
Polymorphism, Single Nucleotide*
Migraine Disorders/*genetics
Alleles ; Cardiovascular System/metabolism ; Case-Control Studies ; Central Nervous System/metabolism ; Genetic Loci ; Humans ; Migraine with Aura/genetics ; Molecular Sequence Annotation ; Quantitative Trait Loci
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Next-generation sequencing identified a novel CACNA1A I1379F variant in a familial hemiplegic migraine type 1 pedigree: A case report.
Autorzy :: Luan H; Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Zhang L; Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Zhang S; Department of Pediatrics, the Second Hospital of Jilin University, Changchun, Jilin, China.
Zhang M; Department of Pediatrics, the Second Hospital of Jilin University, Changchun, Jilin, China.; Pokaż więcej
Źródło :: Medicine [Medicine (Baltimore)] 2021 Dec 23; Vol. 100 (51), pp. e28141.
Typ publikacji :: Case Reports; Journal Article
MeSH Terms :: Calcium Channels/*genetics
Cerebellar Ataxia/*diagnosis
Cerebellar Ataxia/*drug therapy
Migraine Disorders/*diagnosis
Migraine Disorders/*drug therapy
Cerebellar Ataxia/genetics ; Female ; Flunarizine/therapeutic use ; Humans ; Migraine Disorders/genetics ; Migraine with Aura ; Pedigree
SCR Disease Name :: Hemiplegic migraine, familial type 1
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Single-Pulse Transcranial Magnetic Stimulation for the preventive treatment of difficult-to-treat migraine: a 12-month prospective analysis.
Autorzy :: Lloyd JO; Headache Research-Wolfson CARD, Institute of Psychology, Psychiatry and Neuroscience, King's College London, London, UK.
Hill B; The Headache Centre, Guy's and St Thomas NHS Foundation Trust, London, UK.
Murphy M; The Headache Centre, Guy's and St Thomas NHS Foundation Trust, London, UK.
Al-Kaisy A; The Headache Centre, Guy's and St Thomas NHS Foundation Trust, London, UK.
Andreou AP; Headache Research-Wolfson CARD, Institute of Psychology, Psychiatry and Neuroscience, King's College London, London, UK.; The Headache Centre, Guy's and St Thomas NHS Foundation Trust, London, UK.
Lambru G; The Headache Centre, Guy's and St Thomas NHS Foundation Trust, London, UK. .; Institute of Psychology, Psychiatry and Neuroscience, King's College London, London, UK. .; Pokaż więcej
Źródło :: The journal of headache and pain [J Headache Pain] 2022 Jun 06; Vol. 23 (1), pp. 63. Date of Electronic Publication: 2022 Jun 06.
Typ publikacji :: Journal Article
MeSH Terms :: Headache Disorders, Secondary*/etiology
Migraine Disorders*/drug therapy
Migraine Disorders*/prevention & control
Adult ; Headache/etiology ; Humans ; Prospective Studies ; Transcranial Magnetic Stimulation ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Normal glymphatic system function in patients with migraine: A pilot study.
Autorzy :: Lee DA; Department of Neurology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
Lee HJ; Department of Radiology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
Park KM; Department of Neurology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.; Pokaż więcej
Źródło :: Headache [Headache] 2022 Jun; Vol. 62 (6), pp. 718-725. Date of Electronic Publication: 2022 May 11.
Typ publikacji :: Journal Article
MeSH Terms :: Epilepsy*
Glymphatic System*/diagnostic imaging
Glymphatic System*/pathology
Migraine Disorders*
Migraine with Aura*/pathology
Cross-Sectional Studies ; Diffusion Tensor Imaging ; Humans ; Pilot Projects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Vestibular Migraine: Clinical Aspects and Pathophysiology.
Autorzy :: Krishnan PS; Department of Otolaryngology-Head & Neck Surgery, Johns Hopkins School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA; Virginia Commonwealth University School of Medicine, 1201 East Marshall Street, Richmond, VA 23298, USA. Electronic address: https://twitter.com/pkrishhh.
Carey JP; Department of Otolaryngology-Head & Neck Surgery, Johns Hopkins School of Medicine, 601 North Caroline Street, Baltimore, MD 21287, USA. Electronic address: .; Pokaż więcej
Źródło :: Otolaryngologic clinics of North America [Otolaryngol Clin North Am] 2022 Jun; Vol. 55 (3), pp. 531-547. Date of Electronic Publication: 2022 Apr 25.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Migraine Disorders*/diagnosis
Migraine Disorders*/therapy
Vertigo*/diagnosis
Vertigo*/etiology
Vertigo*/therapy
Algorithms ; Headache ; Humans ; Hyperacusis
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache.
Autorzy :: Pensato U; Department of Biomedical and NeuroMotor Sciences of Bologna, University of Bologna, Bologna, Italy.
Baraldi C; Medical Toxicology-Headache and Drug Abuse Research Centre, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Favoni V; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Mascarella D; Department of Biomedical and NeuroMotor Sciences of Bologna, University of Bologna, Bologna, Italy.
Matteo E; Department of Biomedical and NeuroMotor Sciences of Bologna, University of Bologna, Bologna, Italy.
Andrini G; Department of Biomedical and NeuroMotor Sciences of Bologna, University of Bologna, Bologna, Italy.
Cainazzo MM; Medical Toxicology-Headache and Drug Abuse Research Centre, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Cortelli P; Department of Biomedical and NeuroMotor Sciences of Bologna, University of Bologna, Bologna, Italy.; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Pierangeli G; Department of Biomedical and NeuroMotor Sciences of Bologna, University of Bologna, Bologna, Italy.; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Guerzoni S; Medical Toxicology-Headache and Drug Abuse Research Centre, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Cevoli S; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.; Pokaż więcej
Źródło :: Cephalalgia : an international journal of headache [Cephalalgia] 2022 Jun; Vol. 42 (7), pp. 645-653. Date of Electronic Publication: 2022 Feb 09.
Typ publikacji :: Journal Article
MeSH Terms :: Headache Disorders, Secondary*/chemically induced
Headache Disorders, Secondary*/drug therapy
Migraine Disorders*/chemically induced
Migraine Disorders*/drug therapy
Antibodies, Monoclonal/adverse effects ; Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use ; Headache/chemically induced ; Humans ; Prospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.
Autorzy :: Driessen MT; Teva Pharmaceuticals, Piet Heinkade 107, 1019 BR, Amsterdam, The Netherlands. .
Cohen JM; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Thompson SF; Teva Pharmaceuticals, Parsippany, NJ, USA.
Patterson-Lomba O; Analysis Group, Boston, MA, USA.
Seminerio MJ; Teva Pharmaceuticals, Parsippany, NJ, USA.
Carr K; Teva Pharmaceuticals, Parsippany, NJ, USA.
Totev TI; Analysis Group, Boston, MA, USA.
Sun R; Analysis Group, Boston, MA, USA.
Yim E; Analysis Group, Boston, MA, USA.
Mu F; Analysis Group, Boston, MA, USA.
Ayyagari R; Analysis Group, Boston, MA, USA.; Pokaż więcej
Źródło :: The journal of headache and pain [J Headache Pain] 2022 May 16; Vol. 23 (1), pp. 56. Date of Electronic Publication: 2022 May 16.
Typ publikacji :: Journal Article; Randomized Controlled Trial
MeSH Terms :: Depressive Disorder, Major*
Migraine Disorders*/drug therapy
Migraine Disorders*/prevention & control
Adolescent ; Adult ; Antibodies, Monoclonal/therapeutic use ; Calcitonin Gene-Related Peptide/therapeutic use ; Double-Blind Method ; Humans ; Retrospective Studies ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Prevention of medication overuse and medication overuse headache in patients with migraine: a randomized, controlled, parallel, allocation-blinded, multicenter, prospective trial using a mobile software application.
Autorzy :: Diener HC; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany. .
Donoghue S; Curelator Inc., Cambridge, MA, 02139, USA.
Gaul C; Headache Center Frankfurt, Frankfurt, Germany.
Holle-Lee D; Department of Neurology, Center for Translational Neuro- and Behavioral Sciences, University Medicine Essen, Essen, Germany.
Jöckel KH; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany.
Mian A; Curelator Inc., Cambridge, MA, 02139, USA.
Schröder B; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany.; Center for Clinical Trials, University Hospital Essen, Essen, Germany.
Kühl T; Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany.; Center for Clinical Trials, University Hospital Essen, Essen, Germany.; Pokaż więcej
Źródło :: Trials [Trials] 2022 May 11; Vol. 23 (1), pp. 382. Date of Electronic Publication: 2022 May 11.
Typ publikacji :: Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :: Headache Disorders, Secondary*/diagnosis
Headache Disorders, Secondary*/prevention & control
Migraine Disorders*/drug therapy
Migraine Disorders*/prevention & control
Mobile Applications*
Chronic Disease ; Headache ; Humans ; Prescription Drug Overuse/prevention & control ; Prospective Studies ; Recurrence
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 9 9.

Tytuł :: Migraine and balance impairment: Influence of subdiagnosis, otoneurological function, falls, and psychosocial factors.
Autorzy :: Carvalho GF; Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.; Institut für Gesundheitswissenschaften, Studiengang Physiotherapie, Pain and Exercise Research Luebeck (P.E.R.L), Universität zu Lübeck, Lübeck, Germany.
Luedtke K; Institut für Gesundheitswissenschaften, Studiengang Physiotherapie, Pain and Exercise Research Luebeck (P.E.R.L), Universität zu Lübeck, Lübeck, Germany.; Laboratory of Pain Research, The Jerzy Kukuczka Academy of Physical Education, Katowice, Poland.
Pinheiro CF; Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Moraes R; School of Physical Education and Sport of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
Lemos TW; Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Carneiro CG; Department of Ophthalmology, Otolaryngology and Head & Neck Surgery, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Bigal ME; Ventus Therapeutics, Montreal, Quebec, Canada.
Dach F; Department of Neurosciences and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Bevilaqua-Grossi D; Department of Health Sciences, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.; Pokaż więcej
Źródło :: Headache [Headache] 2022 May; Vol. 62 (5), pp. 548-557.
Typ publikacji :: Journal Article
MeSH Terms :: Epilepsy*/complications
Migraine Disorders*/complications
Migraine Disorders*/diagnosis
Migraine with Aura*
Cross-Sectional Studies ; Dizziness/diagnosis ; Dizziness/etiology ; Humans ; Postural Balance ; Vertigo/complications ; Vertigo/diagnosis
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Autorzy :: Ashina M; Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Tepper SJ; Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Brandes JL; Department of Neurology, Vanderbilt University School of Medicine, Nashville Neuroscience Group, Nashville, Tennessee, USA.
Reuter U; Department of Neurology, Charité Universitätsmedizin, Berlin, Germany.; Universitätsmedizin Greifswald, Greifswald, Germany.
Boudreau GP; Centre de Traitement Neurologique, Montreal, Québec, Canada.
Weatherall M; Department of Neurology, Stoke Mandeville Hospital, Aylesbury, UK.
Gantenbein AR; Department for Neurology and Neurorehabilitation, ZURZACH Care, Bad Zurzach, Switzerland.; Department of Neurology, University Hospital Zurich, Zürich, Switzerland.
Doležil D; Prague Headache Center, DADO MEDICAL sro, Prague, Czech Republic.
Klatt J; Novartis Pharma AG, Basel, Switzerland.
Wang A; Amgen Inc., Thousand Oaks, California, USA.
Karanam AK; Novartis Healthcare Private Limited, Hyderabad, India.
Cheng S; Amgen Inc., Thousand Oaks, California, USA.
Mikol DD; Amgen Inc., Thousand Oaks, California, USA.; Pokaż więcej
Źródło :: Headache [Headache] 2022 May; Vol. 62 (5), pp. 624-633.
Typ publikacji :: Journal Article
MeSH Terms :: Antibodies, Monoclonal, Humanized*/adverse effects
Migraine Disorders*/drug therapy
Migraine Disorders*/prevention & control
Calcitonin Gene-Related Peptide Receptor Antagonists/adverse effects ; Double-Blind Method ; Humans ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials.
Autorzy :: Schim JD; Headache Center of Southern California, Carlsbad, California, USA.
Anderson C; Lundbeck LLC, Deerfield, Illinois, USA.
Brunner E; Lundbeck LLC, Deerfield, Illinois, USA.
Hirman J; Pacific Northwest Statistical Consulting, Woodinville, Washington, USA.
Ogbru A; Lundbeck LLC, Deerfield, Illinois, USA.
Cady R; Lundbeck LLC, Deerfield, Illinois, USA.
McGill L; CNS HealthCare, Memphis, Tennessee, USA.; Pokaż więcej
Źródło :: Headache [Headache] 2022 May; Vol. 62 (5), pp. 558-565. Date of Electronic Publication: 2022 May 06.
Typ publikacji :: Journal Article
MeSH Terms :: Migraine Disorders*/drug therapy
Migraine Disorders*/prevention & control
Antibodies, Monoclonal, Humanized ; Double-Blind Method ; Headache ; Humans ; Probability ; Randomized Controlled Trials as Topic ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: A pilot analysis of headache disorders in breast cancer patients.
Autorzy :: De Sanctis R; Medical Oncology and Hematology Unit, IRCCS - Humanitas Clinical and Research Center, Humanitas Cancer Center, Via Manzoni 56, Rozzano, 20089, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090, Milan, Italy.
Viganò A; IRCCS Fondazione Don Carlo Gnocchi, Via Alfonso Capecelatro 66, 20149, Milan, Italy. .
Pindilli S; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090, Milan, Italy.
Torrisi R; Medical Oncology and Hematology Unit, IRCCS - Humanitas Clinical and Research Center, Humanitas Cancer Center, Via Manzoni 56, Rozzano, 20089, Milan, Italy.
Santoro A; Medical Oncology and Hematology Unit, IRCCS - Humanitas Clinical and Research Center, Humanitas Cancer Center, Via Manzoni 56, Rozzano, 20089, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090, Milan, Italy.; Pokaż więcej
Źródło :: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2022 May; Vol. 43 (5), pp. 3313-3320. Date of Electronic Publication: 2021 Nov 24.
Typ publikacji :: Journal Article
MeSH Terms :: Breast Neoplasms*/complications
Breast Neoplasms*/epidemiology
Breast Neoplasms*/therapy
Headache Disorders*/complications
Migraine Disorders*/complications
Migraine Disorders*/diagnosis
Migraine Disorders*/epidemiology
Tension-Type Headache*/complications
Adult ; Aged ; Female ; Headache/complications ; Humans ; Middle Aged
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Myocardial infarction, stroke and cardiovascular mortality among migraine patients: a systematic review and meta-analysis.
Autorzy :: Ng CYH; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Tan BYQ; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Division of Neurology, Department of Medicine, National University Health System, Singapore, Singapore.
Teo YN; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Teo YH; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Syn NLX; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Leow AST; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Ho JSY; Academic Foundation Year Programme, North Middlesex University Hospital Trust, London, UK.
Chan MY; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Department of Cardiology, National University Heart Centre Singapore, National University Health System, Singapore, Singapore.
Wong RCC; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Department of Cardiology, National University Heart Centre Singapore, National University Health System, Singapore, Singapore.
Chai P; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Department of Cardiology, National University Heart Centre Singapore, National University Health System, Singapore, Singapore.
Chan ACY; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Division of Neurology, Department of Medicine, National University Health System, Singapore, Singapore.
Sharma VK; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Division of Neurology, Department of Medicine, National University Health System, Singapore, Singapore.
Yeo LLL; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Division of Neurology, Department of Medicine, National University Health System, Singapore, Singapore.
Sia CH; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. .; Department of Cardiology, National University Heart Centre Singapore, National University Health System, Singapore, Singapore. .
Ong JJY; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Division of Neurology, Department of Medicine, National University Health System, Singapore, Singapore.; Pokaż więcej
Źródło :: Journal of neurology [J Neurol] 2022 May; Vol. 269 (5), pp. 2346-2358. Date of Electronic Publication: 2022 Jan 08.
Typ publikacji :: Journal Article; Meta-Analysis; Review; Systematic Review
MeSH Terms :: Cardiovascular Diseases*/complications
Hemorrhagic Stroke*
Migraine Disorders*/complications
Migraine with Aura*
Myocardial Infarction*/complications
Stroke*/complications
Humans ; Prospective Studies ; Risk Factors
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine.
Autorzy :: Dzator JSA; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan 2308, Australia.
Howe PRC; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan 2308, Australia.; Adelaide Medical School, University of Adelaide, Adelaide 5005, Australia.; Centre for Health Research, University of Southern Queensland, Raceview 4305, Australia.
Coupland KG; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan 2308, Australia.; Hunter Medical Research Institute, New Lambton Heights 2305, Australia.
Wong RHX; School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan 2308, Australia.; Centre for Health Research, University of Southern Queensland, Raceview 4305, Australia.; Pokaż więcej
Źródło :: Nutrients [Nutrients] 2022 Apr 22; Vol. 14 (9). Date of Electronic Publication: 2022 Apr 22.
Typ publikacji :: Journal Article; Randomized Controlled Trial
MeSH Terms :: Migraine Disorders*/drug therapy
Migraine Disorders*/prevention & control
Quality of Life*
Adult ; Cross-Over Studies ; Dietary Supplements ; Double-Blind Method ; Female ; Headache ; Humans ; Resveratrol/therapeutic use ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Migraine-Associated Mutation in the Na,K-ATPase Leads to Disturbances in Cardiac Metabolism and Reduced Cardiac Function.
Autorzy :: Staehr C; Department of Biomedicine, Health Aarhus University Aarhus Denmark.
Rohde PD; Department of Chemistry and Bioscience Aalborg University Aalborg Denmark.
Krarup NT; Department of Cardiology Viborg Regional Hospital Viborg Denmark.
Ringgaard S; MR Research Centre Department of Clinical Medicine Aarhus University Aarhus Denmark.
Laustsen C; MR Research Centre Department of Clinical Medicine Aarhus University Aarhus Denmark.
Johnsen J; Department of Clinical Medicine Aarhus University Aarhus Denmark.
Nielsen R; Department of Biomedicine, Health Aarhus University Aarhus Denmark.
Beck HC; Department for Clinical Biochemistry and Pharmacology Odense University Hospital Odense Denmark.
Morth JP; Department of Biotechnology and Biomedicine Technical University of Denmark Kgs. Lyngby Denmark.
Lykke-Hartmann K; Department of Biomedicine, Health Aarhus University Aarhus Denmark.; Department of Clinical Medicine Aarhus University Aarhus Denmark.; Department of Clinical Genetics Aarhus University Hospital Aarhus Denmark.
Jespersen NR; Department of Clinical Medicine Aarhus University Aarhus Denmark.
Abramochkin D; Department of Human and Animal Physiology Biological Faculty Lomonosov Moscow State University Moscow Russia.
Nyegaard M; Department of Biomedicine, Health Aarhus University Aarhus Denmark.; Department of Health Science and Technology Aalborg University Aalborg Denmark.
Bøtker HE; Department of Clinical Medicine Aarhus University Aarhus Denmark.
Aalkjaer C; Department of Biomedicine, Health Aarhus University Aarhus Denmark.; Department of Biomedical Sciences Copenhagen University Copenhagen Denmark.
Matchkov V; Department of Biomedicine, Health Aarhus University Aarhus Denmark.; Pokaż więcej
Źródło :: Journal of the American Heart Association [J Am Heart Assoc] 2022 Apr 05; Vol. 11 (7), pp. e021814. Date of Electronic Publication: 2022 Mar 15.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Heart*/physiopathology
Migraine Disorders*
Migraine with Aura*/metabolism
Sodium-Potassium-Exchanging ATPase*/genetics
Animals ; Heterozygote ; Mice ; Mutation ; Myocardium/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: A real-world, observational study of erenumab for migraine prevention in Canadian patients.
Autorzy :: Becker WJ; Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.
Spacey S; Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada.
Leroux E; Brunswick Medical Center, Montreal, Quebec, Canada.
Giammarco R; Hamilton Headache Clinic, Hamilton, Ontario, Canada.
Gladstone J; Gladstone Headache Clinic, Toronto, Ontario, Canada.
Christie S; Ottawa Headache Centre Inc., Ottawa, Ontario, Canada.
Akaberi A; IQVIA Solutions Canada Inc., Montreal, Quebec, Canada.
Power GS; IQVIA Solutions Canada Inc., Mississauga, Ontario, Canada.
Minhas JK; IQVIA Solutions Canada Inc., Ottawa, Ontario, Canada.
Mancini J; IQVIA Solutions Canada Inc., Montreal, Quebec, Canada.
Rochdi D; Novartis Canada, Dorval, Quebec, Canada.
Filiz A; Novartis Canada, Dorval, Quebec, Canada.
Bastien N; Novartis Canada, Dorval, Quebec, Canada.; Pokaż więcej
Źródło :: Headache [Headache] 2022 Apr; Vol. 62 (4), pp. 522-529. Date of Electronic Publication: 2022 Apr 10.
Typ publikacji :: Journal Article; Observational Study
MeSH Terms :: Calcitonin Gene-Related Peptide Receptor Antagonists*
Migraine Disorders*/chemically induced
Migraine Disorders*/drug therapy
Migraine Disorders*/prevention & control
Adult ; Analgesics/therapeutic use ; Antibodies, Monoclonal, Humanized ; Canada ; Double-Blind Method ; Humans ; Prospective Studies ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Polygenic risk provides biological validity for the ICHD-3 criteria among Finnish migraine families.
Autorzy :: Häppölä P; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.
Gormley P; GlaxoSmithKline, Cambridge, MA, USA.; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.; Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Nuottamo ME; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.; Folkhälsan Research Center, Helsinki, Finland.
Artto V; Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland.
Sumelahti ML; Faculty of Medicine and Health, University of Tampere, Tampere, Finland.
Nissilä M; Terveystalo Clinical Research, Turku, Finland.
Keski-Säntti P; Terveystalo, Helsinki, Finland.
Ilmavirta M; Department of Neurology, Central Hospital Central Finland, Jyväskylä, Finland.
Kaunisto MA; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.
Hämäläinen EI; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.
Ripatti S; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Public Health, Clinicum, University of Helsinki, Helsinki, Finland.
Pirinen M; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.; Department of Public Health, Clinicum, University of Helsinki, Helsinki, Finland.; Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland.
Wessman M; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.; Folkhälsan Research Center, Helsinki, Finland.
Palotie A; Institute for Molecular Medicine Finland FIMM, HiLIFE, University of Helsinki, Helsinki, Finland.; Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.; Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Analytic and Translational Genetics Unit, Department of Medicine, and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Kallela M; Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland.; Pokaż więcej
Corporate Authors :: International Headache Genetics Consortium (IHGC)
Źródło :: Cephalalgia : an international journal of headache [Cephalalgia] 2022 Apr; Vol. 42 (4-5), pp. 345-356. Date of Electronic Publication: 2021 Oct 14.
Typ publikacji :: Journal Article
MeSH Terms :: Headache Disorders*
Migraine Disorders*/diagnosis
Migraine Disorders*/genetics
Migraine with Aura*/diagnosis
Finland/epidemiology ; Headache ; Humans
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Persistent monocular visual loss in migraine patients.
Autorzy :: Rodrigues SG; Neurology Department, Hospital da Luz de Lisboa, Avenida Lusíada nº100, 1500-650, Lisboa, Portugal. .
Gouveia RG; Neurology Department, Hospital da Luz de Lisboa, Avenida Lusíada nº100, 1500-650, Lisboa, Portugal.; Pokaż więcej
Źródło :: Acta neurologica Belgica [Acta Neurol Belg] 2022 Apr; Vol. 122 (2), pp. 437-440. Date of Electronic Publication: 2021 Jul 29.
Typ publikacji :: Journal Article
MeSH Terms :: Epilepsy*
Migraine Disorders*/complications
Migraine Disorders*/diagnosis
Migraine with Aura*/complications
Migraine with Aura*/diagnostic imaging
Retinal Vasculitis*
Female ; Humans ; Scotoma/etiology ; Vision Disorders
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Lifestyle impact on migraine during home confinement.
Autorzy :: Granato A; Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Headache Centre, University Hospital and Health Services of Trieste - ASUGI, University of Trieste, Strada Di Fiume, 447, 34149, Trieste, Italy.
Furlanis G; Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Headache Centre, University Hospital and Health Services of Trieste - ASUGI, University of Trieste, Strada Di Fiume, 447, 34149, Trieste, Italy.
D'Acunto L; Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Headache Centre, University Hospital and Health Services of Trieste - ASUGI, University of Trieste, Strada Di Fiume, 447, 34149, Trieste, Italy.
Olivo S; Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Headache Centre, University Hospital and Health Services of Trieste - ASUGI, University of Trieste, Strada Di Fiume, 447, 34149, Trieste, Italy.
Buoite Stella A; Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Headache Centre, University Hospital and Health Services of Trieste - ASUGI, University of Trieste, Strada Di Fiume, 447, 34149, Trieste, Italy.
Manganotti P; Clinical Unit of Neurology, Department of Medicine, Surgery and Health Sciences, Headache Centre, University Hospital and Health Services of Trieste - ASUGI, University of Trieste, Strada Di Fiume, 447, 34149, Trieste, Italy. .; Pokaż więcej
Źródło :: Acta neurologica Belgica [Acta Neurol Belg] 2022 Apr; Vol. 122 (2), pp. 497-503. Date of Electronic Publication: 2022 Feb 11.
Typ publikacji :: Journal Article
MeSH Terms :: COVID-19*
Migraine with Aura*/complications
Migraine without Aura*/complications
Communicable Disease Control ; Humans ; Life Style
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations.
Autorzy :: Tepper SJ; Department of Neurology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Sheikh HU; Department of Neurology, Mt. Sinai-Icahn School of Medicine, New York, New York, USA.
Dougherty CO; Department of Neurology, Medstar Georgetown University Hospital, Washington, DC, USA.
Nahas SJ; Department of Neurology, Thomas Jefferson University, Jefferson Headache Center, Philadelphia, Pennsylvania, USA.
Winner PK; Premiere Research Institute, Nova Southeastern University, West Palm Beach, Florida, USA.
Karanam AK; Novartis Healthcare Private Limited, Hyderabad, India.
Blumenfeld AM; The Los Angeles Headache Center, Los Angeles, California, USA.; The San Diego Headache Center, San Diego, California, USA.
Abdrabboh A; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Rasmussen S; Amgen Inc., Thousand Oaks, California, USA.
Weiss JL; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Ailani J; Department of Neurology, Medstar Georgetown University Hospital, Washington, DC, USA.; Pokaż więcej
Źródło :: Headache [Headache] 2022 Apr; Vol. 62 (4), pp. 420-435. Date of Electronic Publication: 2022 Feb 09.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Calcitonin Gene-Related Peptide Receptor Antagonists*
Migraine Disorders*/drug therapy
Migraine Disorders*/prevention & control
Adult ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Humans ; Randomized Controlled Trials as Topic ; Receptors, Calcitonin Gene-Related Peptide
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""migraine"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język